Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors in the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advancements study identified that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://daveyi862neq3.thechapblog.com/profile